Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
23
pubmed:dateCreated
2009-6-9
pubmed:abstractText
Substitution mutations in the BRAF serine/threonine kinase are found in a variety of human cancers. Such mutations occur in approximately 70% of human malignant melanomas, and a single hyperactivating V600E mutation is found in the activation segment of the kinase domain and accounts for more than 90% of these mutations. Given this correlation, the molecular mechanism for BRAF regulation as well as oncogenic activation has attracted considerable interest, and activated forms of BRAF, such as BRAF(V600E), have become attractive targets for small molecule inhibition. Here we report on the identification and subsequent optimization of a potent BRAF inhibitor, CS292, based on an organometallic kinase inhibitor scaffold. A cocrystal structure of CS292 in complex with the BRAF kinase domain reveals that CS292 binds to the ATP binding pocket of the kinase and is an ATP competitive inhibitor. The structure of the kinase-inhibitor complex also demonstrates that CS292 binds to BRAF in an active conformation and suggests a mechanism for regulation of BRAF by phosphorylation and BRAF(V600E) oncogene-induced activation. The structure of CS292 bound to the active form of the BRAF kinase also provides a novel scaffold for the design of BRAF(V600E) oncogene selective BRAF inhibitors for therapeutic application.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-10205168, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-10704835, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-12068308, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-12591721, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-14678966, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-14741289, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-15035987, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-15059882, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-15466206, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-15493898, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-15520807, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-16260133, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-16417378, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-16551863, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-16858717, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-17145850, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-17210701, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-17375909, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-17406720, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-18287029, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-18300768, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-18484710, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-1862342, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-1862343, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-6308607, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-6319999, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-6325930, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-7935411, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-7935430, http://linkedlifedata.com/resource/pubmed/commentcorrection/19371126-7962002
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1520-4995
pubmed:author
pubmed:issnType
Electronic
pubmed:day
16
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5187-98
pubmed:dateRevised
2011-9-26
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
pubmed:affiliation
The Wistar Institute, Philadelphia, Pennsylvania 19104-6323, USA.
pubmed:publicationType
Journal Article, Research Support, N.I.H., Extramural